Previous studies found that disclosure does not lead to significant depression or anxiety symptoms in APOE-ε4 carriers in the short term, both in controlled research trials [24, 25, 50] and in direct-to-consumer testing [51]. The gene discussed is APOE; the disease is depressive symptom measurement.